CONFERENCE OVERVIEW

Tuck's second annual healthcare conference will bring together leaders in industry, policy and academia to examine the effect of the recent emergence of biogenerics on the biotech industry and patient care. 

Keynote Address: The Challenge of Biosimilars:  Is the Juice Worth the Squeeze? 

The keynote address will review issues associated with the manufacture of therapeutic proteins, the challenges those issues raise for biosimilar producers as well as the impact of pending biosimilar legislation on the biotechnology marketplace.

Two panels presented in the meeting will provide in-depth understanding and discussion in the following interesting and urgent issues.

Panel 1:  Biogenerics Regulation: The Evolution of an Industry

Research and Advisory firm Decision Resources predicts that the market for biogenerics in the U.S. will grow to $2B by 2016, and that large biotech players are bracing for an erosion in the sales of their branded products.  However, how and when this growth will take place is unclear, as the U.S. stills lacks a regulatory framework for biogenerics. This panel will examine how the U.S. regulatory climate is likely to evolve, how an approved regulatory path for biogenerics will impact patients and the healthcare system and what effects this may have on the industry globally. It will also explore why Europe has been able to establish a regulatory framework in advance of the U.S. and whether there are lessons for the U.S. in the European experience.

 Panel 2:  Biogenerics: Global Impact on Patients and the Biotech Industry

This panel will examine whether biogenerics will adversely affect patient health or result in superior drugs. It will also explore whether biogenerics will drive down the costs to patients and 3rd-party payers, and result in better access to drugs. Finally, panelists will discuss the implications of all of these developments on established biotech players,  emerging biotech, and biogeneric companies globally.

Speakers: 

 C. Everett Koop, MD, D’37, Former U.S. Surgeon General & Founder and Senior Scholar of the C. Everett Koop Institute at Dartmouth

Steven Gillis, PhD, A’78, Managing Partner, ARCH Venture Partners & Founder of Immunex Corporation

The Honorable James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO)

Keith O. Webber, Ph.D., Deputy Director, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Alexis Ahlstrom, Director, Avalere Health, LLC

John H. (Jack) Turco, MD, Director, Dartmouth College Health Service & Associate Professor of Medicine, Dartmouth Medical School

Andrew J. Hirsch T’97, Vice President, Business Planning, Biogen Idec

Greg D. Butz T’06, Associate, Western Region Healthcare Practice, Morgan Stanley

Anna Schwamlein Howard, Senior Legislative Representative, Federal Health and Long-Term Care Team, Government Relations and Advocacy, AARP

Jim Roach, MD, Chief Medical Officer, Momenta Pharmaceuticals

Errik B. Anderson D'00 T'07, Vice President, Operations & Finance, Adimab, Inc.

Donald P. Conway T'72, Director, The Healthcare Initiative & Adjunct Associate Professor of Business Administration, Tuck School; Director, MD/MBA Program at Dartmouth; Adjunct Associate Professor, Dartmouth Medical School